Mucosa

Yazarlar: ["Timothy COWAN", "Nada ABU ALRUB", "Anna WİLSON", "Mani MAKHİJA", "Dedee MURRELL"]

Konular:-

DOI:10.33204/mucosa.1209480

Anahtar Kelimeler:Biyolojik,Keilit,Tildrakizumab,Interlökin-23,Dermatoloji

Özet: Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.

---